Developing a theme
Ground a sector thesis in business models, value pools and the capabilities an attractive asset should possess.
Investor advisory · Private equity
The market story is only the beginning.
A good business can still be the wrong investment. A difficult business can still hold overlooked value. The difference is often found below the presentation—in how the company makes money, what the strategy requires and whether the team can deliver it.
01Look beneath the thesis
From presentation to business reality
Every process arrives with a version of the future.
The market is growing. The platform is differentiated. The model shows what happens when the assumptions hold. The investor still needs to understand what must be true for the story to work.
An attractive market cannot compensate for a business without the capabilities to capture it. Growth may depend too heavily on one customer, product, contract or leader. A platform may look scalable while the operating model beneath it remains fragmented.
Ingenium helps private equity teams move from a credible narrative to a clearer view of the asset itself—connecting sector dynamics, operating reality, management capability and the work ownership will require.
Common starting points
Useful when a question will shape the investment.
Ingenium may enter before an asset is known, during diligence, at the investment committee or after a portfolio company begins to drift from plan.
Evaluating an asset
Understand market position, commercial logic and where deeper diligence should concentrate.
Reading a specialist market
See the service model inside the wider healthcare-commercialization chain.
Preparing for committee
Pressure-test the strategic rationale, assumptions and principal sources of risk.
Testing management
Examine whether the current leaders fit the scale and complexity of the future strategy.
Resetting a portfolio plan
Distinguish real value-creation priorities from an attractive but unsupported list of initiatives.
Across the investment lifecycle
Before the deal. During the work. After the close.
The questions change as the investment moves forward. Ingenium can support one moment or remain involved as the situation develops.
Theme development
Where could value exist, and why now?
Asset identification
Which companies express the thesis?
Diligence
What is differentiated, credible and at risk?
Value creation
Which few priorities can change the investment?
Board & leadership
How should ownership support delivery?
Sector experience changes the questions
Know where to look.
Specialty pharmaceutical commercialization is not one industry. It is a connected system in which a change in one part can reshape the economics elsewhere.
The value of experience is not knowing every answer before diligence begins. It is recognizing which assumptions deserve pressure and which details may matter more than they first appear.
Read the asset withinthe whole commercialization system
01ManufacturersTherapy strategy · launches · market access
02Distribution & logisticsInventory · availability · cold chain · capital
03Pharmacies & providersSite of care · capacity · clinical operations
04Payers & patient servicesReimbursement · access · adherence · support
05Technology & dataWorkflow · evidence · visibility · coordination
Specialty distributionSpecialty pharmacyInfusion & home healthcareThird-party logisticsHUB & patient servicesRare & orphan pharmacyCell & gene therapyOncology servicesClinical-trial logisticsCold-chain packagingBiosimilarsHealthcare technology
Diligence beyond the data room
Information is not the same as understanding.
The work complements legal, accounting and specialist diligence by making the commercial and operating implications easier to see.
Customer choice
Why do customers choose the company, and how durable is that reason?
Differentiation
Which capabilities genuinely matter rather than merely sound distinctive?
Scalability
Can the commercial and operating model grow without losing its economics?
Dependency
How exposed is the business to key people, contracts, customers or partners?
Economics
Where are margin and capital created, consumed or placed at risk?
Execution
What infrastructure, talent and decisions will management’s plan require?
The plan still needs people who can deliver it
The future strategy may demand a different version of the team.
A founder may need to lead inside a formal ownership structure. A strong functional executive may need to become an enterprise leader. A CEO who runs today’s company well may be less prepared to integrate acquisitions or operate at larger scale.
01
What are the strengths of the current leadership team?
02
Does the team fit the future strategy and ownership environment?
03
Where are responsibilities unclear or critical capabilities missing?
04
How do leaders work together when pressure rises?
05
Which changes are urgent—and which need more evidence?
From thesis to operating priorities
Value creation must survive contact with the business.
A long list of opportunities is not yet a value-creation plan. The work is to identify the few priorities capable of materially changing the investment.
01
Protect what already creates value
Understand the capabilities and relationships the plan cannot afford to weaken.
02
Choose where the business can expand
Separate genuine permission to grow from adjacency that only looks attractive.
03
Sequence constrained resources
See which initiatives depend on the same people, systems and capital.
04
Define what ownership should monitor
Connect strategy, leadership and operating milestones to the board’s view.
Experience as an operator
Responsibility for the result—not only the recommendation.
At ASD Healthcare, Matt inherited an underperforming specialty-distribution business with strong service capabilities and significant operating problems. The business was stabilized, repositioned and scaled with greater financial and operating discipline.
Revenue growth over six years, 2012–2018
Improvement in committed or working capital
Top-box customer satisfaction reached
Increase in employee engagement
Building capabilities through M&A
A transaction should make strategic sense before it becomes a financial model.
Matt’s experience connects three parts of private equity work that are often separated: deciding why an asset is attractive, understanding what needs to change and carrying responsibility for the result.
His transaction work has supported new services, stronger market positions, enabling technology, new geographies, manufacturer and patient-support capabilities, clinical-trial logistics, specialty pharmacy, infusion and adjacent distribution.
After the transaction
Ownership creates the next set of questions.
- Board membership and advisory roles
- Lead independent director responsibilities
- CEO and C-suite coaching
- Leadership assessment and team decisions
- Strategy and value-creation discussions
- Founder and leadership transitions
Selected transaction experience
World Courier · TheraCom · Bellco · IntrinsiQ · Innomar Strategies · IgG America · Xcenda · H. D. Smith · NovoLogix
The Ingenium approach
Focused on the decision that matters.
- 01
Define the question
Clarify the asset, thesis, concern or decision.
- 02
Understand the context
Review the company, market, management and transaction information.
- 03
Find critical assumptions
Identify the few conditions that most affect the case.
- 04
Test the business logic
Examine the model, market position and path to value.
- 05
Examine leadership
Consider the team and board where material to the thesis.
- 06
Share a clear perspective
Discuss confidence, uncertainty and further diligence.
- 07
Define what follows
End with the decision—or continue into ownership support.
Useful to the decision
Make the investment team clearer, not merely better informed.
Sector and market perspectiveAsset and business-model reviewCritical diligence questionsManagement strengths and gapsValue-creation prioritiesBoard and governance considerations
Clear boundaries
Ingenium’s role centers on strategy, market understanding, operating implications, leadership and value creation. It does not replace legal, tax, accounting, clinical, regulatory or other specialist diligence.
Questions private equity teams ask
A flexible role, shaped around the investment.
At what point is Ingenium engaged?+
Most often when a firm is evaluating a specific company, but the work can begin with theme development or continue into post-close board and leadership support.
Can Ingenium assess management?+
Yes, where management capability is material to the investment. The scope can include interviews, assessment or broader leadership review.
Can Matt join the board after investment?+
Matt considers board-member, lead-director and board-advisor roles where the situation and fit are appropriate.
Does Ingenium only work with large firms?+
No. Matt’s experience spans founder-owned, lower middle-market, middle-market and larger private equity environments.
See the business behind the investment case
Tell us what you are evaluating—and what you still need to understand.
It may be a market, a specific asset, a management team or a value-creation plan that needs a more experienced test.